ClinicalTrials.gg
CompletedNCT00375193Updated Oct 24, 2019

Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy

A Phase 2 interventional study of Amrubicin in Small Cell Lung Cancer, sponsored by Celgene. Completed at 46 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-24.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb — 2 open to participants now, 2 under way, 1 of them phase 3. Small Cell Lung Carcinoma · Bristol-Myers Squibb.

Enrollment
13th of 17
75 · median 92
Started
2006
with 2 others
Phase 2
6 of 19
none open now
Registered
2nd of 19
by date

Among the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, this one is the 13th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2006, is one of 6 in phase 2, and was the 2nd registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the objective tumor response rate of amrubicin when administered as second-line therapy to ED-SCLC patients who have refractory or progressive disease.

03

Conditions studied

  • Small Cell Lung Cancer

Keywords

  • small cell lung cancer
  • amrubicin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of SCLC; extensive-disease (ED) at time of study entry
  • to platinum-based chemotherapy (i.e., has received one prior platinum-based chemotherapy regimen) defined as one of the following:

    • Best response to first-line chemotherapy is radiographically documented progression (refractory disease)
    • Best response to first-line chemotherapy is radiographically documented response or stable disease, with subsequent documented progression during continuing chemotherapy (resistant relapse)
    • Documented progression within 90 days of completion of first-line chemotherapy (last dose of chemotherapy), regardless of best response to treatment (resistant relapse)
  • At least 18 years of age
  • Performance Status of 0, 1, or 2
  • defined by criteria

    • Measurable disease: The presence of at least one measurable lesion. If only one lesion is present, the neoplastic nature of the disease site should be confirmed by histology and/or cytology.
    • Measurable lesion: Lesions that can be accurately measured in at least one dimension with the longest diameter ≥20mm using conventional techniques or ≥10mm using spiral CT scans.
  • CT (including spiral CT) scans and MRI are the preferred methods of measurement; however, chest x-rays are acceptable if the lesions are clearly defined and surrounded by aerated lung. Clinically detected lesions will only be considered measurable when they are superficial (e.g., skin nodules and palpable lymph nodes). For the case of skin lesions, documentation by color photography, including a ruler to estimate the size of the lesion is required.
  • Adequate organ function including the following:

    • Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) ≥1500 cells/μL, count ≥100,000 cells/μL and ≥9g/dL.
    • Hepatic: ≤ 1.5 X ; (ALT) and aspartate aminotransferase (AST) ≤ 3.0 X ULN.
    • Renal: serum creatinine \< 2.0 mg/dL or calculated >60 mL/min.
    • Cardiac: (LVEF) ≥ 50% by MUGA or echocardiography (intra-patient reassessment of LVEF should be performed via the same method throughout the study).
  • Negative serum pregnancy test at the time of enrollment for women of . For men and women of child-bearing potential, use of effective methods during the study.
  • Ability to understand the requirements of the study, provide written and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing women
  • Chest radiotherapy within the previous 28 days or other radiotherapy within the previous 14 days. Recovery from the acute toxic effects of radiation required prior to study enrollment. that have been previously irradiated must be enlarging to be considered target lesions. Prior radiation therapy allowed to \< 25% of the bone marrow.
  • More than 1 prior chemotherapy regiment for SCLC
  • Prior anthracycline treatment
  • Treatment with any agent within 28 days or standard chemotherapy within 21 days prior to first dose. Patients must have recovered from all acute adverse effecxts of prior therapies, excluding alopecia
  • Patients with secondary primary (except in situ carcinoma of the cervix or adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated at least 2 years previously with surgery and/or radiotherapy and no evidence of recurrence since that time)
  • Concurrent severe or uncontrolled medical disease (i.e., active systemic infection, diabetes, hypertension, coronary artery disease, congestive heart failure) that, in the opinion of the Investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study.
  • Symptomatic central nervous system . Patients with asymptomatic are allowed. The patient must be stable after radiotherapy for ≥ 2 weeks and off for ≥ 1 week.
  • History of interstitial lung disease or pulmonary fibrosis.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    1

    Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until cycle 6 or no longer beneficial.

    Drug: Amrubicin

Interventions

  • Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until Cycle 6 or no longer beneficial

06

What researchers measure

Primary outcomes

  1. Objective tumor response rate according to RECIST

    Time frame: Until Disease Progression

Secondary outcomes

  1. Duration of overall response

    Time frame: Until Disease Progression

  2. Time to tumor progression

    Time frame: Until Disease Progression

  3. Progression free survival

    Time frame: Until death or disease progression

  4. Overall survival

    Time frame: Until death

  5. Toxicity profile

    Time frame: Until 30 days after final dose

  6. Incidence of cardiomyopathy

    Time frame: Until end of study participation

  7. Incidence of CNS progression

    Time frame: Until disease progression

  8. Pharmacokinetic parameters

    Time frame: Cycle 1 only

07

Study locations

46 sites
  • Hematology Oncology Associates
    Phoenix, Arizona 85012, United States
  • Rocky Mountain Cancer Center - Sky Ridge
    Lone Tree, Colorado 80124, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Cancer Centers of Florida, PA
    Ocoee, Florida 34761, United States
  • John B. Amos Cancer Center
    Columbus, Georgia 31904, United States
  • Cancer Care & Hematology Specialists of Chicago
    Niles, Illinois 60714, United States
  • Oncology & Hematology of Central Illinois
    Peoria, Illinois 61602, United States
  • Blessing Cancer Center
    Quincy, Illinois 62301, United States
  • Central Indiana Cancer Centers - Indianapolis
    Indianapolis, Indiana 46227, United States
  • Norton Healthcare - Louisville Oncology
    Louisville, Kentucky 40202, United States
  • Maryland Oncology Hematology, PA
    Columbia, Maryland 21044, United States
  • Alliance Hematology Oncology, PA - Carroll County Cancer Center
    Westminster, Maryland 21157, United States
  • West Michigan Cancer Center
    Kalamazoo, Michigan 49007, United States
  • Minnesota Onc/Hem, PA - Minneapolis
    Minneapolis, Minnesota 55404, United States
  • University of MN/Division of Hematology, Oncology & Transplantation
    Minneapolis, Minnesota 55455, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • St. Joseph Oncology, Inc.
    Saint Joseph, Missouri 64507, United States
  • Arch Medical Group - Arch Medical Services, Inc.
    Saint Louis, Missouri 63141, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89109, United States
  • New York Oncology Hematology, PC
    Albany, New York 12208, United States
  • SUNY Upstate Medical Center
    Syracuse, New York 13210, United States
  • Northwestern Carolina Oncology & Hematology
    Hickory, North Carolina 28602, United States
  • Raleigh Hematology Oncology Associates
    Raleigh, North Carolina 27607, United States
  • Willamette Valley Cancer Center
    Eugene, Oregon 97401, United States
  • Medical Oncology Associates
    Kingston, Pennsylvania 18704, United States
  • University of Tennessee Medical Center, Knoxville
    Knoxville, Tennessee 37920, United States
  • Sarah Cannon
    Nashville, Tennessee 37203, United States
  • Texas Oncology - Amarillo
    Amarillo, Texas 79106, United States
  • Mamie McFaddin Ward Cancer Center
    Beaumont, Texas 77702-1449, United States
  • Texas Oncology, PA - Bedford
    Bedford, Texas 76022, United States
  • Texas Cancer Center at Medical City
    Dallas, Texas 75230-2510, United States
  • Texas Oncology, P.A. - Dallas
    Dallas, Texas 75246, United States
  • Texas Oncology, P.A., Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Texas Oncology, PA - Fort Worth
    Fort Worth, Texas 76104, United States
  • West Texas Cancer Center
    Odessa, Texas 79761, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Texas Oncology Cancer Care and Research Center
    Waco, Texas 76712, United States
  • Texas Oncology, PA - Deke Slayton Cancer Center
    Webster, Texas 77598, United States
  • Texas Oncology - Wichita Falls
    Wichita Falls, Texas 76310, United States
  • Virginia Oncology Associates - Norfolk, VA
    Norfolk, Virginia 23502, United States
  • Oncology & Hematology Associates of Southwest Virginia, Inc.
    Salem, Virginia 24153, United States
  • Puget Sound Cancer Center
    Seattle, Washington 98133, United States
  • Northwest Cancer Specialists - Vancouver Cancer Center
    Vancouver, Washington 98684, United States
  • Yakima Regional Cancer Care Center - North Star Lodge Cancer Center
    Yakima, Washington 98902, United States
  • Free University Medical Center
    Amsterdam, NL 1081 HV, Netherlands
  • Royal Marsden Hospital in Downs Road
    Sutton, Surrey, United Kingdom
08

References and documents

Publications

  • Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, Conkling P, Spigel DR, Dudek AZ, Shah C, Salgia R, McNally R, Renschler MF, Oliver JW. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010 May 20;28(15):2598-603. doi: 10.1200/JCO.2009.26.7682. Epub 2010 Apr 12. PubMed 20385980 ↗
  • Spigel DR, et al. Amrubicin (AMR) and cardiotoxicity in second-line treatment of small cell lung cancer (SCLC): A pooled analysis of left ventricular ejection fraction (LVEF) in two phase II trials. 2009 ASCO Annual Meeting, May 29-June 2, 2009, Chicago, IL. Abstract No.e19019. J Clin Oncol 2009;27(suppl)
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2006 to primary completion in May 2008, 18 months.

Of 54 industry-sponsored phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 44. This study's 18 months is below that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2006
First posted
Sep 12, 2006
StartActual
Nov 1, 2006
Primary completionActual
May 1, 2008
CompletionActual
Mar 1, 2009
Results delay requested
May 19, 2009
Last update
Oct 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00375193
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Sep 12, 2006
Start date
Nov 1, 2006
Primary completion
May 1, 2008
Completion
Mar 1, 2009
Last update
Oct 24, 2019

Study contacts

Richard S Ungerleider, MD
study director · Theradex

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amrubicin

Start the discussion